	US 12,220,487 B2
	Sustained release compositions comprising micronized tolcapone
Anna Nardi Ricart, Barcelona (ES); Josep Maria Suñé Negre, Barcelona (ES); Núria Reig Bolaño, Barcelona (ES); Raúl Insa Boronat, Barcelona (ES); Oscar Huertas Gambín, Barcelona (ES); Santiago Esteva Gras, Barcelona (ES); and Gal-la Pericot Mohr, Barcelona (ES)
Assigned to Som Innovation Biotech, S.L., Barcelona (ES)
Filed by Som Innovation Biotech, S.L., Barcelona (ES)
Filed on Jan. 29, 2024, as Appl. No. 18/425,739.
Application 18/425,739 is a continuation of application No. 16/321,336, granted, now 11,883,538, previously published as PCT/EP2017/069168, filed on Jul. 28, 2017.
Claims priority of application No. 16382372 (EP), filed on Jul. 29, 2016.
Prior Publication US 2024/0216282 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/20 (2006.01); A61K 31/12 (2006.01); A61K 31/122 (2006.01)

CPC A61K 9/2054 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2095 (2013.01); A61K 31/12 (2013.01); A61K 31/122 (2013.01)]

20 Claims

1. A sustained release tablet for oral administration comprising: (a) micronized tolcapone having a particle size distribution characterized in that its D_V,0.9is not greater than 70 μm, (b) a release retardant, and (c) a binder, wherein a proportion of tolcapone dissolved after 5 hours in the conditions of USP36 Tolcapone monograph is not higher than 90% of the total amount of tolcapone in the tablet.